Jon Napitupulu

Iovance Biotherapeutics will host its fourth quarter and full-year 2025 results call and webcast on February 24, 2026, at...

Ascendis Pharma closed 2025 with a sharp inflection in rare endocrine commercialization, reporting €684 million in product revenue for...

Psyence Biomedical has settled a shareholder dispute with Kaos Capital, agreeing to pay US$1.5 million, waive a prior C$75,000...

Veru plans to initiate a Phase 2b “Plateau” study this quarter testing enobosarm, an oral selective androgen receptor modulator,...

AscellaHealth has expanded its international leadership, elevating Gillian Molloy to general manager of international operations and appointing Alexis Moss...

Avicanna has closed a non-brokered private placement totaling C$1.55 million, issuing 7,750,001 units at C$0.20 each. Each unit comprises...

Neuronetics posted preliminary, unaudited fourth-quarter 2025 revenue of $41.8 million and full-year revenue of $149.2 million, with positive operating...

Exousia Pro has signed a third letter of intent to acquire an established telehealth organization, expanding a roll-up that...

Sanofi has completed its acquisition of Dynavax Technologies, adding the marketed adult hepatitis B vaccine Heplisav-B and a Phase...

Day One Biopharmaceuticals will host its fourth-quarter and full-year 2025 results call on February 24, 2026, at 4:30 p.m....